Adjuvant Immune Checkpoint Inhibitors in Postoperative Hepatocellular Carcinoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Though hepatectomy is one of the curative treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. However, no study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Przeprowadzono operacyjne usunięcie części wątroby
- •Rak wątroby potwierdzony badaniem tkanki po operacji
- •Dobra funkcja wątroby (stopień A lub B)
- •Ogólny stan zdrowia pacjenta dobry (klasa 0 lub 1)
- •Wysoki риск powrotu raka (guz ≥5 cm, wiele guzów lub nacieczenie naczyń)
✗ Disqualifies
- •Wcześniejsze leczenie immunologiczne przed operacją
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 75 Years
- Last updated (source)
- October 7, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Jian-Hong Zhong
Nanning, China
Trial contact
Jian-Hong Zhong, PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.